Tag: biosimilars fda

Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters

Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian HamstersNeutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters

| GregoryGregory | 0 Comment

The extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the principle goal for neutralizing antibodies. These antibodies might be elicited by means of immunization or passively transferred as

READ MOREREAD MORE